AAPL355.63+7.12 (+2.04%) ▲|ABBV294.98+1.09 (+0.37%) ▲|ABT109.29-1.17 (-1.06%) ▼|ACN253.66-4.85 (-1.88%) ▼|ADBE237.60+0.90 (+0.38%) ▲|AMAT395.08+22.55 (+6.05%) ▲|AMD552.90+37.69 (+7.32%) ▲|AMGN468.11+2.88 (+0.62%) ▲|AMT190.24-0.13 (-0.07%) ▼|AMZN266.17-4.70 (-1.74%) ▼|AVGO345.22+13.24 (+3.99%) ▲|AXP323.11-0.35 (-0.11%) ▼|BA174.54+1.16 (+0.67%) ▲|BAC50.67-0.01 (-0.02%) ▼|BKNG160.21+0.95 (+0.60%) ▲|BLK1,226.31+4.16 (+0.34%) ▲|BMY62.91+0.11 (+0.18%) ▲|BNY152.69+1.55 (+1.03%) ▲|BRK-B588.24+4.90 (+0.84%) ▲|C124.21+1.94 (+1.59%) ▲|CAT601.61+17.04 (+2.92%) ▲|CL98.00-0.09 (-0.09%) ▼|CMCSA25.02+0.27 (+1.09%) ▲|COF197.11+1.27 (+0.65%) ▲|COP137.86+2.27 (+1.67%) ▲|COST1,087.61+21.47 (+2.01%) ▲|CRM218.01+4.53 (+2.12%) ▲|CSCO100.76+2.61 (+2.66%) ▲|CVS89.52+0.51 (+0.57%) ▲|CVX213.28+2.06 (+0.98%) ▲|DE691.75+4.11 (+0.60%) ▲|DHR235.31-0.80 (-0.34%) ▼|DIS119.65+0.44 (+0.37%) ▲|DUK128.77-0.17 (-0.13%) ▼|EMR167.06-0.48 (-0.29%) ▼|FDX322.63+3.15 (+0.99%) ▲|GD367.22-0.22 (-0.06%) ▼|GE342.75+4.84 (+1.43%) ▲|GEV808.24+11.20 (+1.41%) ▲|GILD169.73-1.14 (-0.67%) ▼|GM88.90+0.21 (+0.24%) ▲|GOOG290.63+5.71 (+2.00%) ▲|GOOGL293.45+6.07 (+2.11%) ▲|GS926.81+16.62 (+1.83%) ▲|HD351.31+0.31 (+0.09%) ▲|HON227.64-0.58 (-0.25%) ▼|IBM248.22+3.69 (+1.51%) ▲|INTC62.50+4.37 (+7.52%) ▲|INTU342.64+2.20 (+0.65%) ▲|ISRG449.53-0.51 (-0.11%) ▼|JNJ280.41-0.37 (-0.13%) ▼|JPM343.39+1.32 (+0.39%) ▲|KO97.57+0.66 (+0.68%) ▲|LIN526.55+4.77 (+0.91%) ▲|LLY1,437.29+5.00 (+0.35%) ▲|LMT610.05+6.93 (+1.15%) ▲|LOW231.60-0.27 (-0.12%) ▼|LRCX235.88+13.49 (+6.07%) ▲|MA660.73+1.89 (+0.29%) ▲|MCD274.80-7.37 (-2.61%) ▼|MDLZ66.70+0.16 (+0.24%) ▲|MDT101.61+0.02 (+0.02%) ▲|META628.77-12.62 (-1.97%) ▼|MMM188.88-0.49 (-0.26%) ▼|MO77.39+1.05 (+1.38%) ▲|MRK147.18-0.87 (-0.59%) ▼|MS190.61+3.05 (+1.63%) ▲|MSFT521.13-12.04 (-2.26%) ▼|MU811.30+86.19 (+11.89%) ▲|NEE85.99-0.28 (-0.32%) ▼|NFLX64.54+1.28 (+2.02%) ▲|NKE38.32-0.35 (-0.91%) ▼|NOW102.76+3.15 (+3.16%) ▲|NVDA173.73+4.93 (+2.92%) ▲|ORCL128.38+10.40 (+8.82%) ▲|PEP143.94+0.33 (+0.23%) ▲|PFE29.45+0.09 (+0.31%) ▲|PG167.67-0.99 (-0.59%) ▼|PLTR172.40+3.58 (+2.12%) ▲|PM196.35+2.10 (+1.08%) ▲|QCOM176.57+3.04 (+1.75%) ▲|RTX201.29+1.02 (+0.51%) ▲|SBUX109.89-0.06 (-0.05%) ▼|SCHW92.78-0.25 (-0.27%) ▼|SO93.84+0.19 (+0.20%) ▲|SPG234.75+0.27 (+0.12%) ▲|T22.26+0.32 (+1.46%) ▲|TMO717.71-0.49 (-0.07%) ▼|TMUS172.16+3.08 (+1.82%) ▲|TSLA390.84+11.06 (+2.91%) ▲|TXN309.81+9.29 (+3.09%) ▲|UBER70.68+0.63 (+0.90%) ▲|UNH402.94-2.18 (-0.54%) ▼|UNP302.11+1.49 (+0.50%) ▲|UPS112.45+1.40 (+1.26%) ▲|USB60.70-0.05 (-0.08%) ▼|V425.55+2.55 (+0.60%) ▲|VZ46.60+0.29 (+0.63%) ▲|WFC85.80+0.04 (+0.05%) ▲|WMT125.67+0.12 (+0.10%) ▲|XOM166.71+2.24 (+1.36%) ▲|AAPL355.63+7.12 (+2.04%) ▲|ABBV294.98+1.09 (+0.37%) ▲|ABT109.29-1.17 (-1.06%) ▼|ACN253.66-4.85 (-1.88%) ▼|ADBE237.60+0.90 (+0.38%) ▲|AMAT395.08+22.55 (+6.05%) ▲|AMD552.90+37.69 (+7.32%) ▲|AMGN468.11+2.88 (+0.62%) ▲|AMT190.24-0.13 (-0.07%) ▼|AMZN266.17-4.70 (-1.74%) ▼|AVGO345.22+13.24 (+3.99%) ▲|AXP323.11-0.35 (-0.11%) ▼|BA174.54+1.16 (+0.67%) ▲|BAC50.67-0.01 (-0.02%) ▼|BKNG160.21+0.95 (+0.60%) ▲|BLK1,226.31+4.16 (+0.34%) ▲|BMY62.91+0.11 (+0.18%) ▲|BNY152.69+1.55 (+1.03%) ▲|BRK-B588.24+4.90 (+0.84%) ▲|C124.21+1.94 (+1.59%) ▲|CAT601.61+17.04 (+2.92%) ▲|CL98.00-0.09 (-0.09%) ▼|CMCSA25.02+0.27 (+1.09%) ▲|COF197.11+1.27 (+0.65%) ▲|COP137.86+2.27 (+1.67%) ▲|COST1,087.61+21.47 (+2.01%) ▲|CRM218.01+4.53 (+2.12%) ▲|CSCO100.76+2.61 (+2.66%) ▲|CVS89.52+0.51 (+0.57%) ▲|CVX213.28+2.06 (+0.98%) ▲|DE691.75+4.11 (+0.60%) ▲|DHR235.31-0.80 (-0.34%) ▼|DIS119.65+0.44 (+0.37%) ▲|DUK128.77-0.17 (-0.13%) ▼|EMR167.06-0.48 (-0.29%) ▼|FDX322.63+3.15 (+0.99%) ▲|GD367.22-0.22 (-0.06%) ▼|GE342.75+4.84 (+1.43%) ▲|GEV808.24+11.20 (+1.41%) ▲|GILD169.73-1.14 (-0.67%) ▼|GM88.90+0.21 (+0.24%) ▲|GOOG290.63+5.71 (+2.00%) ▲|GOOGL293.45+6.07 (+2.11%) ▲|GS926.81+16.62 (+1.83%) ▲|HD351.31+0.31 (+0.09%) ▲|HON227.64-0.58 (-0.25%) ▼|IBM248.22+3.69 (+1.51%) ▲|INTC62.50+4.37 (+7.52%) ▲|INTU342.64+2.20 (+0.65%) ▲|ISRG449.53-0.51 (-0.11%) ▼|JNJ280.41-0.37 (-0.13%) ▼|JPM343.39+1.32 (+0.39%) ▲|KO97.57+0.66 (+0.68%) ▲|LIN526.55+4.77 (+0.91%) ▲|LLY1,437.29+5.00 (+0.35%) ▲|LMT610.05+6.93 (+1.15%) ▲|LOW231.60-0.27 (-0.12%) ▼|LRCX235.88+13.49 (+6.07%) ▲|MA660.73+1.89 (+0.29%) ▲|MCD274.80-7.37 (-2.61%) ▼|MDLZ66.70+0.16 (+0.24%) ▲|MDT101.61+0.02 (+0.02%) ▲|META628.77-12.62 (-1.97%) ▼|MMM188.88-0.49 (-0.26%) ▼|MO77.39+1.05 (+1.38%) ▲|MRK147.18-0.87 (-0.59%) ▼|MS190.61+3.05 (+1.63%) ▲|MSFT521.13-12.04 (-2.26%) ▼|MU811.30+86.19 (+11.89%) ▲|NEE85.99-0.28 (-0.32%) ▼|NFLX64.54+1.28 (+2.02%) ▲|NKE38.32-0.35 (-0.91%) ▼|NOW102.76+3.15 (+3.16%) ▲|NVDA173.73+4.93 (+2.92%) ▲|ORCL128.38+10.40 (+8.82%) ▲|PEP143.94+0.33 (+0.23%) ▲|PFE29.45+0.09 (+0.31%) ▲|PG167.67-0.99 (-0.59%) ▼|PLTR172.40+3.58 (+2.12%) ▲|PM196.35+2.10 (+1.08%) ▲|QCOM176.57+3.04 (+1.75%) ▲|RTX201.29+1.02 (+0.51%) ▲|SBUX109.89-0.06 (-0.05%) ▼|SCHW92.78-0.25 (-0.27%) ▼|SO93.84+0.19 (+0.20%) ▲|SPG234.75+0.27 (+0.12%) ▲|T22.26+0.32 (+1.46%) ▲|TMO717.71-0.49 (-0.07%) ▼|TMUS172.16+3.08 (+1.82%) ▲|TSLA390.84+11.06 (+2.91%) ▲|TXN309.81+9.29 (+3.09%) ▲|UBER70.68+0.63 (+0.90%) ▲|UNH402.94-2.18 (-0.54%) ▼|UNP302.11+1.49 (+0.50%) ▲|UPS112.45+1.40 (+1.26%) ▲|USB60.70-0.05 (-0.08%) ▼|V425.55+2.55 (+0.60%) ▲|VZ46.60+0.29 (+0.63%) ▲|WFC85.80+0.04 (+0.05%) ▲|WMT125.67+0.12 (+0.10%) ▲|XOM166.71+2.24 (+1.36%) ▲|
13.3 C
New York
Thursday, November 12, 2026

Tag: PHA BIO MTC HEA

newsFORsourcecompanycontentinformationreleases1IT

AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026

THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of...

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

-     Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combinations.-     ASC36o, a once-weekly oral amylin receptor peptide agonist, is...

Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity

-     Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combinations.-     ASC36o, a once-weekly oral amylin receptor peptide agonist, is...

WuXi AppTec Receives Frost & Sullivan’s Global Company of the Year Recognition in CRDMO for Tenth Consecutive Year

SHANGHAI, Oct. 19, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received Frost & Sullivan's...

AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-α4β7 Monotherapy in Moderate to Severe...

In a Phase 2a study, ABBV-466 achieved higher endoscopic remission rates in patients with Crohn's disease than either anti-IL-23 p19 or anti-α4β7 monotherapy at...

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical...

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse...

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentationUpdated first-line...

XtalPi Nominates Its First siRNA Preclinical Candidate for IgA Nephropathy Nine Months After Program Initiation

Preclinical data demonstrate subnanomolar silencing potency, achieving an IC50 tens of times lower than the corresponding values for two clinical-stage reference molecules targeting the...

Neuroendocrine Prostate Cancer Market to Witness Growth at a 25% CAGR by 2036 Due to the Emergence of Emerging agents, including DLL3-targeted Therapies, ADCs,...

The neuroendocrine prostate cancer market is expected to grow steadily, driven by the rising recognition of NEPC as an aggressive and treatment-resistant form of...

The Expanding Peptide Conjugate Landscape: Strategies for Complex Peptide Synthesis, Upcoming Webinar Hosted by Xtalks

In this free webinar, learn how synthesis strategies can support the development of increasingly complex peptide conjugates. The featured speaker will discuss route selection,...

Vector Science & Therapeutics Corp. Appoints Russell Starr as President

Capital markets executive and long-time Company stakeholder joins senior leadership to help drive Vector's next phase of growthTORONTO, Oct. 14, 2026 /PRNewswire/ -- Vector...

Legacy Healthcare’s CINAINU® Receives FDA Breakthrough Therapy Designation for Alopecia Areata in Adults, Adolescents and Children Aged 2 Years and Older

EPALINGES, Switzerland, Oct. 13, 2026 /PRNewswire/ -- Legacy Healthcare, a biopharmaceutical company developing innovative botanical prescription drugs, today announced that the U.S. Food and...

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for the Treatment of Advanced Prostate Cancer; Changchun GeneScience Pharmaceutical will Commercialize in China

TAIPEI, Oct. 12, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that it was notified by its licensing partner, Changchun GeneScience Pharmaceutical...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPHA BIO MTC HEA

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers